9th Annual Biomarkers Congress

Cancer Biology: Johnson & Johnson

Total Score People Score Events Score
39 23 36
Date Event Presentation Speakers
October 16, 2013 Drug Discovery Re-Invented; Emerging Role of Biotechs, Academics and Non-Profits Collaborative Drug Discovery II Bart DeCorte
May 23, 2012 Biomarkers World Europe 2012 Using receptor occupancy in the drug discovery process John Atack
November 12, 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Overcoming barriers to new drug development William Hait
January 31, 2011 Biomarkers Summit STREAM ONE | URINARY BIOMARKERS IN THE CLINICAL PROGNOSIS AND EARLY DETECTION OF ACUTE KIDNEY INJURY (AKI) Hans Winkler
September 27, 2010 Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development Session 3A: From Bench to Bedside Yixin Wang
May 20, 2010 Bioanalytical Challenges for Optimizing Protein Therapeutics Reagent Selection & Management Adrienne Clements-Egan
February 24, 2010 5th Annual Bioanalysis in Clinical Research Towards European Pharma companies best practice on metabolite quantification Philip Timmerman
November 6, 2009 Clinical Applications for Age Management Medicine Continental Breakfast Catherine Oyler
September 24, 2009 TRACK 1: Optimizing Clinical Trials : Third Annual clinical biomarkers Enabling Personalized Medicine through Application of Biomarkers in Clinical Development Nicholas C. Dracopoli
September 24, 2009 Track 2: Implementing Personalized Medicine : Inaugural Targeted Therapy Enabling Personalized Medicine through Application of Biomarkers in Clinical Development Nicholas C. Dracopoli
September 24, 2009 Track 3:Advancing Cancer Therapy : Inaugural Circulating Tumor Cells Enabling Personalized Medicine through Application of Biomarkers in Clinical Development Nicholas C. Dracopoli
September 24, 2009 Track 4: Bridging Silos in Biomarker Development : Seventh Annual Protein Biomarkers Enabling Personalized Medicine through Application of Biomarkers in Clinical Development Nicholas C. Dracopoli
September 23, 2009 Track 2: Implementing Personalized Medicine : Inaugural Personalized Medicine Industry Perspective on Companion Diagnostics and Drug Labels Nadine Cohen
September 23, 2009 Track 3: Advancing Cancer Therapy : Second Annual Translational Cancer Medicine Circulating Tumor Cells: From Enumeration to Comprehensive Characterization Nicholas C. Dracopoli
August 5, 2009 New Frontiers in Cancer Drug Development Translational Medicine: Predictive and Pharmacodynamic Biomarkers in Cancer Drug Development Nicholas C. Dracopoli
August 5, 2009 Targets in Context - Linking Targets to Diseases Agenda Confirmation of JNJ-38877605 as a selective c-Met kinase inhibitor using quantitative chemical proteomics. Tim Perera
June 9, 2009 Cell and Tissue-Based Assays for HTS Cell-Based Assays in Drug Discovery – So Many Choices, So Little Time Lisa Minor
Chairperson’s Remarks Lisa Minor
Continental Breakfast Breakout Discussions Table Four: Choosing the Right System and Approach for Each Assay Lisa Minor
June 9, 2009 Translating Genomic Knowledge Biomarker Applications in Drug Development Nicholas C. Dracopoli
April 7, 2009 Inaugural HIV Inhibitors Topic 12: The Future of Natural Products in Drug Discovery Bart DeCorte
Featured Presentation: The Discovery of Intelence®, an Important Advance in the Treatment of HIV Bart DeCorte
December 2, 2008 4th Annual Global Imaging Summit -The Application of Molecular and Cellular Imaging in Drug Discovery & Optimising Imaging Techniques in Preclinical and Clinical Drug Development 2 : Use of WBA (whole body autoradioluminography) to study tissue distribution of compounds in the early and late stages of preclinical trials Katelijne Anciaux,
October 22, 2008 HDAC Inhibitors: Targeting Oncology and Beyond JNJ-26481585 - a novel second-generation oral pan-HDAC inhibitor Janine Arts
October 21, 2008 20th EORTC - NCI - AACR Symposium on "Molecular Targets and Cancer Therapeutics" Plenary session 4 Novel therapeutic targets within the autophagic pathway William N Hait
June 18, 2008 Accelerating Anticancer Agent Development and Validation Workshop Faculty William N Hait
May 30, 2008 ASCO Annual'08 Meeting professional development-- Mid-Career Changes: Why, How, and When? William Hait
March 25, 2008 Mastering Medicinal Chemistry Discovery of Benzodiazepinone Inhibitors of the p53:HDM2 Interaction Mark R Player
Fused Pyrimidine Heterocycles as Selective 5-HT2A Antagonists Brock T Shireman
March 25, 2008 R&D Risk Mitigation Predictive Response Biomarkers – Theory and Practice Hans Winkler
March 25, 2008 TRANSLATIONAL MEDICINE Predictive Response Biomarkers – Theory and Practice Hans Winkler
February 19, 2008 Screening Europe Track A A Comparison of Cell-Based Label-Free Assay Tools Lisa Minor
November 5, 2007 Second Annual Biomarkers Europe Nov (05-06) BIOMARKERS IN PERSONALIZED MEDICINE: Discovery and Evaluation of Predictive Response Gene Expression Signatures (14:30-15:00) Hans Winkler
BIOMARKERS IN PERSONALIZED MEDICINE (13:10-17:00) Hans Winkler
November 4, 2007 AACR Centennial Conference: Translational Cancer Medicine Culture, Policy, and Economics of Cancer research and cancer Care: Global Perspective William N Hait
October 16, 2007 Inaugural HDAC inhibitors: Meeting the Challenges of Chemical Development of HDAC Inhibitors Oct (16 -17) NEXT GENERATION HDAC INHIBITORS (10:35-12:40) Janine Arts
NEXT GENERATION HDAC INHIBITORS: JNJ-26481585 - A Novel “Second-generation” Oral Pan-Histone Deacetylase (HDAC) Inhibitor - Shows Broad-spectrum Preclinical Antitumoral Activity Against Solid and Haematological Malignancies (12:10-12:40) Janine Arts
October 16, 2007 Fifth Annual RNAi for Drug Discovery and Therapeutics - Best Practices from the Bench to the Clinic Oct (16-17) RNAi as a Predictive Tool (14:20-15:25) Pieter Peeters
RNAi as a Predictive Tool: Chairperson’s Remarks (14:20-14:45) Pieter Peeters
RNAi FOR IN VIVO TARGET VALIDATION (16:30-19:30) Pieter Peeters
RNAi FOR IN VIVO TARGET VALIDATION: Efficient in vivo Knock-down of Genes in the Peripheral/Central Nervous System (17:30-18:00) Pieter Peeters
Roundtable Discussion Topic: In vivo RNAi Screening (07:30-08:30) Pieter Peeters
October 15, 2007 Thirs Annual Quantitative PCR, MicroArrays, And Biologican Validation: Capturing the Complete Biological Story (Oct 15-17) Enhancing Platform Performance (08:45-14:00) Elisa Mokany
Enhancing Platform Performance: New Real-time PCR Technology, Mediated by Multi-Component Nucleic Acid Enzymes (MNAzymes); has a Superior Capacity for Multiplex Analysis (08:55-09:25) Elisa Mokany
October 15, 2007 Cambridge Healthtech Institute's Third Annual Mastering Process Chemistry Oct (15-17) PROCESS OPTIMIZATION VIA ANALYTICS: Isolation of the Drug Substance Impurities at 0.05–0.1% Level Using At-Column Dilution, Mass-Driven Collection, and Comprehensive Automation of the Entire Process (16:05-16:35) Michael Breslav
PROCESS OPTIMIZATION VIA ANALYTICS (14:00-15:05) Michael Breslav
September 30, 2007 Bridging Pharma and IT - Leveraging Information Technology to Improve Productivity (Sep30-Oct2) BRIDGING DISCOVERY/DEVELOPMENT AND IT (09:30-15:30) Simson Alex, Victor Lobanov
BRIDGING DISCOVERY/DEVELOPMENT AND IT: Advancing Upload and Storage of Assay Data (11:45-12:30) Victor Lobanov
September 17, 2007 Biomarker Discovery Summit: Bridging the Silos in Biomarker Discovery & Validation (Sep17-19) Third annual Genomic Biomarkers: VALIDATION OF GENOMIC BIOMARKERS: Discovery and Validation of Biomarkers Affected by Brivanib and Erbitux (11:30-12:00) J. Suso Platero
Third annual Genomic Biomarkers: VALIDATION OF GENOMIC BIOMARKERS (11:30-14:00) J. Suso Platero
Third annual Genomic Biomarkers: BIOMARKERS FOR CLINICAL TRIALS: Discovery and Evaluation of Predictive Response Gene Expression Signatures (14:00-14:30) Hans Winkler
Third annual Genomic Biomarkers: BIOMARKERS FOR CLINICAL TRIALS (14:00-16:00) Hans Winkler
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.